Date: 2014-03-24
Type of information: Series A financing round
Company: CAP-CMV (Germany)
Investors: Peppermint Venture Partners (PVP) (Germany), NRW.Bank (Germany), Creathor Venture (Germany), KfW (Germany), private investors
Amount: € 1.7 million
Funding type: series A financing round
Planned used: The funds will be used to advance further CAP-CMV´s vaccine candidate, HCMV dense bodies (DBs) derived from CEVEC´s human CAP cell technology. DBs contain highest amount of relevant antigens, and were shown to elicit strong and lasting humoral and cellular immune responses in preclinical models. The money will be used to prove in various animal studies the advantages of this system against other technologies as well as advancing pre-clinical programs.
Others: * On March 24, 2014, CAP-CMV GmbH, a company focusing exclusively on the development of a novel vaccine protecting against human cytomegalovirus (hCMV) infection, has announced that it raised in total € 1.7 m from its investors Peppermint Venture Partners (PVP), NRW.Bank, Creathor Venture, KfW and private investors in a combined seed/start-up investment. Also in March CAP-CMV´s shareholders appointed Albrecht Läufer as its new CEO. Albrecht Läufer was cofounder and first CEO of Vakzine Projekt Management GmbH (VPM), the company which has started preclinical development of HCMV dense bodies and then licensed the project to CAP-CMV.
Therapeutic area: Infectious diseases
